RBCM
ABBV icon

Raub Brock Capital Management’s AbbVie ABBV Stock Holding History

Raub Brock Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Sell
63,763
-15,698
-20% -$3.38M 4.42% 4
2026
Q1 		$17.3M Sell
79,461
-9,805
-11% -$2.17M 4.38% 4
2025
Q4 		$20.4M Sell
89,266
-3,319
-4% -$756K 4.54% 5
2025
Q3 		$21.4M Sell
92,585
-1,767
-2% -$360K 4.61% 5
2025
Q2 		$17.5M Sell
94,352
-3,127
-3% -$581K 3.82% 10
2025
Q1 		$20.4M Sell
97,479
-5,798
-6% -$1.13M 4.56% 3
2024
Q4 		$18.4M Buy
103,277
+854
+0.8% +$157K 3.9% 13
2024
Q3 		$20.2M Sell
102,423
-2,306
-2% -$430K 4.11% 10
2024
Q2 		$18M Sell
104,729
-1,555
-1% -$258K 3.92% 8
2024
Q1 		$19.4M Sell
106,284
-6,624
-6% -$1.14M 4.1% 9
2023
Q4 		$17.5M Sell
112,908
-25,870
-19% -$3.77M 3.67% 16
2023
Q3 		$20.7M Sell
138,778
-4,092
-3% -$601K 4.11% 12
2023
Q2 		$19.2M Sell
142,870
-1,764
-1% -$259K 3.61% 20
2023
Q1 		$23.1M Buy
144,634
+2,928
+2% +$448K 4.43% 4
2022
Q4 		$22.9M Sell
141,706
-17,979
-11% -$2.76M 4.68% 3
2022
Q3 		$21.4M Sell
159,685
-21,442
-12% -$3.08M 4.47% 7
2022
Q2 		$27.7M Sell
181,127
-26,888
-13% -$4.11M 5.3% 2
2022
Q1 		$33.7M Sell
208,015
-39,654
-16% -$5.76M 5.74% 1
2021
Q4 		$26.7M Hold
247,669
– – 4.06% 14
2021
Q3 		$26.7M Sell
247,669
-2,637
-1% -$301K 4.06% 14
2021
Q2 		$28.2M Sell
250,306
-6,082
-2% -$685K 4.86% 11
2021
Q1 		$27.7M Sell
256,388
-6,850
-3% -$733K 4.38% 9
2020
Q4 		$28.2M Sell
263,238
-5,940
-2% -$571K 4.57% 5
2020
Q3 		$23.6M Sell
269,178
-1,673
-0.6% -$158K 4% 14
2020
Q2 		$26.6M Sell
270,851
-16,057
-6% -$1.41M 4.94% 1
2020
Q1 		$21.9M Sell
286,908
-9,262
-3% -$789K 4.77% 2
2019
Q4 		$26.2M Buy
+296,170
New +$24.6M 4.6% 7

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Raub Brock Capital Management's ABBV Position: Q2 2026 in Review

Raub Brock Capital Management reduced its AbbVie (ABBV) stake by 20% in Q2 2026, selling an estimated $3.38M and leaving 63,763 shares worth $16M. The position accounts for 4.42% of the portfolio, ranked #4.

Raub Brock Capital Management first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $33.7M in Q1 2022. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Raub Brock Capital Management held 63,763 shares of AbbVie worth $16M as of Q2 2026.
  • Raub Brock Capital Management sold 15,698 AbbVie shares in Q2 2026, an estimated $3.38M.
  • AbbVie made up 4.42% of Raub Brock Capital Management's portfolio in Q2 2026, its #4 holding.
  • Raub Brock Capital Management first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Raub Brock Capital Management's AbbVie position peaked at $33.7M in Q1 2022.
  • 4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Raub Brock Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.